Tezepelumab Drug Asset Due Diligence Report 2026

This Tezepelumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

104

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tezepelumab can convert its Monoclonal antibody profile and TSLP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tezepelumab (query alias: tezepelumab)
Modality / target	Monoclonal antibody; TSLP; TSLP inhibitors
Highest global status	Approved
Originator	AstraZeneca AB
Active developers	Amgen, Inc., AstraZeneca PLC, AstraZeneca AB

The MCP disease footprint includes Chronic rhinosinusitis with nasal polyps, Severe asthma, Asthma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07363642	Phase 3	Recruiting	400	To assess the potential for Tezepelumab treated patients to reduce their standard of care asthma controller regimen in the overall patient population while maintaining asthma control
NCT07520162	Phase 3	Recruiting	230	To describe changes from baseline in nasal polyp score (NPS)
JPRN-UMIN000061957	Not Applicable	一般募集中/Open public recruiting	70	健常者・重症喘息患者の末梢血肥満細胞前駆細胞数およびその関連分子の比較・関連

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SUNRISE)

Phase 3; n=125; evaluation: not stated. Reported fields: Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.: Cumulative Odds Ratio = 2.93(95% CI, 1.43 - 6.03), P-Value = 0.003; Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.: Cumulative Odds Ratio = 2.93(95% CI, 1.43 - 6.03), P-Value = 0.003; Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.: Cumulative Odds Ratio = 2.93(95% CI, 1.43 - 6.03), P-Value = 0.003

Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial

Phase 3; n=122; evaluation: Positive. Reported fields: AE = 72.0 % ; AE = 57.0 %

Effectiveness of Tezepelumab in T2-High Asthma: A Target Trial Emulation using Active Comparators

Not Applicable; n=90; evaluation: Positive. Reported fields: Cumulative risk of exacerbations(1-year) = 57.8 % ( 39.5 - 74.8); Cumulative risk of exacerbations(1-year) = 48.5 % ( 30.8 - 67.9)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tezepelumab addresses Chronic rhinosinusitis with nasal polyps, Severe asthma, Asthma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2012-04-02	Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio	Phase 1	US$50.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Inhaler and capsule for delivering thymic stromal lymphopoietin (TSLP)-binding antibodies”. The milestone feed surfaced a patent-application signal described as “Compositions of thymic stromal lymphopoietin (TSLP) binding fragments and methods of use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO